Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships. - Wikidata - wikimedia - TriplyDB

Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships.

Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships.

http://www.wikidata.org/entity/Q38153040

about

Cell Membrane-Coated Nanoparticles As an Emerging Antibacterial Vaccine Platform Unusual Biosynthesis and Structure of Locillomycins from Bacillus subtilis 916 The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models.Novel platform technology for modular mucosal vaccine that protects against streptococcus.The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells.A high-performance thioredoxin-based scaffold for peptide immunogen construction: proof-of-concept testing with a human papillomavirus epitope.Targeting TLR2 for vaccine development Therapeutic cyclic lipopeptides mining from microbes: latest strides and hurdles.Recent advances in the molecular design of synthetic vaccines.Skin-Specific Unsaturated Fatty Acids Boost the Staphylococcus aureus Innate Immune Response.Mycobacterium tuberculosis lipoproteins in virulence and immunity - fighting with a double-edged sword.Lipoprotein immunoproteomics question the potential of Staphylococcus aureus TLR2 agonists as vaccine antigens.6-(4-Amino-2-butyl-imidazoquinolyl)-norleucine: Toll-like receptor 7 and 8 agonist amino acid for self-adjuvanting peptide vaccine.Bacillomycin L and surfactin contribute synergistically to the phenotypic features of Bacillus subtilis 916 and the biocontrol of rice sheath blight induced by Rhizoctonia solani.Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics.

P2860

Q26784233-DE3A83B4-324C-49E0-95C1-3EBCB36C341E Q36033311-B51FFDE4-9881-4F9C-A629-D0A1513DF43A Q36599857-8DC0A18A-848E-4715-8DBE-F861D8558010 Q37504796-D8C244D1-1E0F-4C2B-BEE6-76D3A6496BB5 Q37653873-D672B33F-33EF-481F-A05E-EED3EEBE589D Q37714750-81EBFAA8-ECD9-4C8F-8717-CE02C7F9FB1F Q38233376-3F63A0FA-9531-4D3B-8D03-089C536A932E Q38515064-C24BB5BA-C87A-4DB3-BDB6-B80363A7215B Q38639938-8AC7B201-16EE-47F1-A418-9FB022FC9C4F Q38824843-0ACEABF5-3718-4F65-A212-3CDD1E30A468 Q38878969-5FA99011-A0D4-4A60-A680-23D700FE24E9 Q40528006-171186D4-9120-4932-B45C-53EAF14A5912 Q40911284-9C32AD37-7C83-4DE1-9EBB-7F07BE73897A Q41660835-1ECEE724-1A43-4F15-B993-E388DDEDD4ED Q47590580-639BCBE4-7446-4C8D-919A-C4601268BAEA

P2860

Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships.

http://www.wikidata.org/entity/Q38153040

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Immunostimulation by synthetic ...... ucture-activity relationships.

@en

type

label

Immunostimulation by synthetic ...... ucture-activity relationships.

@en

prefLabel

Immunostimulation by synthetic ...... ucture-activity relationships.

@en

P1433

Q38153040-BEE16F80-4A95-4A48-BBBB-975193419A30

P1476

Q38153040-AC6BCF7B-A94B-4F2F-B72F-85662FBCE6D6

P2093

Q38153040-80CCCB0F-4407-4366-9A99-26B2D0545695

P2860

Q38153040-0BA25A7E-8834-4154-9BFD-7259638A3431

Q38153040-0D4AB333-E608-40D6-BC48-76754CF7A63C

Q38153040-0FB0FC32-1E1C-4F5E-B340-066248993A78

Q38153040-1168252C-CAF8-4944-9269-3C05A1161646

Q38153040-21A09D98-1856-4B90-A4E1-B822D421A79B

Q38153040-240F2F13-6379-4857-8200-78A18DEF5CF3

Q38153040-253A8FE5-A61D-452C-AF26-B074D096AB79

Q38153040-2B98C22B-7D7A-48F9-8FA6-19EE39C7451B

Q38153040-2FE80F44-5805-47C6-B853-1366ABD8AE6D

Q38153040-327DDBC5-BAFC-4AEE-8447-897D4F490388

P304

Q38153040-44D7536D-01D9-47EC-A1D8-65F7FFB2E895

P31

Q38153040-14D649CF-63AB-46CE-A463-32F7069A9CAD

P356

Q38153040-B6CB7F05-FD25-4836-AB2C-CD4C0AE1BF2C

P478

Q38153040-AF4E42D7-597E-4205-BDDF-AE7A0A933F3A

P50

Q38153040-17CDEF7E-8D63-4DB8-9A0D-68DC8495A3F3

P577

Q38153040-E8258EC8-8BDB-4DF0-9926-CB8CD1D62430

P5875

Q38153040-0EDBD110-5BF0-4AFC-B00E-604C6F777A2B

P698

Q38153040-66486A6B-AECB-456A-A28B-EEE014E4FCE8

P932

Q38153040-A198FBF5-5E22-4426-879E-DEE020082E19

P356

FIMMU.2013.00318

P1433

Frontiers in Immunology

P1476

Immunostimulation by synthetic ...... ucture-activity relationships.

@en

P2093

Mehfuz Zaman

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccines: from empirical development to rational design

Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction

Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide

Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer

TLR signaling pathways

Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling

Pyrexia, anorexia, adipsia, and depressed motor activity in rats during systemic inflammation induced by the Toll-like receptors-2 and -6 agonists MALP-2 and FSL-1

Significance of bacterial surface-active compounds in interaction of bacteria with interfaces

The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling

P304

318

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FIMMU.2013.00318

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257839852

http://www.w3.org/2001/XMLSchema#string

P698

24130558

http://www.w3.org/2001/XMLSchema#string

P932

3793171

http://www.w3.org/2001/XMLSchema#string